The US beat back bird flu in 2025 – but the battle isn’t over

H5N1 avian influenza, first detected in poultry in 1996 and resurging in 2021, began infecting US dairy cattle in March 2024 and has since been found in more than 1,080 herds across 19 states while also affecting poultry (at least 1,950 flocks since Feb 2022 and nearly 200 million birds culled). US human infections total 71 as of December 2025 with one US death; most cases traced to dairy or poultry exposure. Authorities have scaled back the emergency response after declines in cattle detections and implementation of measures including the USDA National Milk Testing Strategy (Dec 2024) and a $1 billion poultry mitigation plan (Feb), but experts warn ongoing mammal infections and migration-season risk keep pandemic potential elevated, implying continued downside risk to poultry/dairy supply chains and biosecurity-sensitive equities.

Analysis

Market structure: Agricultural producers of animal vaccines, animal-health inputs and feed (Zoetis ZTS, Elanco ELAN, Merck MRK animal-health unit) are clear winners from the USDA’s $1B program and mandated milk testing; expect pricing power on vaccine contracts and biosecurity services to lift revenue +5-15% over 12 months for niche providers. Losers include commercial poultry and specialty dairy names (Tyson TSN, Pilgrim’s Pride PPC, Cal-Maine CALM) facing culling, lost supply and biosecurity costs; EBITDA pressure of 10-30% is plausible in the next 2-4 quarters if outbreaks re-emerge. Competitive dynamics: larger integrated animal-health incumbents gain share (scale in vaccine deployment, distribution), pressuring smaller biotech startups unless they secure fast government contracts; barriers to entry rise as testing and cold-chain capacity become important.

Risk assessment: Tail risk—an adaptive H5 strain with sustained human-to-human transmission—remains low probability (<5% in 12 months) but catastrophic; it would cause severe dislocation across consumer cyclicals and aviation and trigger risk-off flows. Near-term (days–weeks) watch for headline volatility around any new human cases; medium-term (3–9 months) risk centers on migration season (Sept–Feb) and herd-testing results; long-term (12–36 months) the path depends on vaccine approval/adoption and structural changes to livestock farming. Hidden dependencies include under-reporting if worker surveillance drops and the pace of USDA fund disbursement which materially affects contract awards and supply-chain remediation.

Trade implications: Favor 6–12 month tactical longs in ZTS (2–3% portfolio) and MRK (animal-health exposure) vs. shorts in TSN and PPC via 3–6 month put spreads sized 1–2% each; buy CORN ETF (CORN) 3–9 month exposure (1%) as protein rebalancing can lift feed demand and prices. Options: purchase 3–6 month 15–25 delta puts on TSN and PPC (or buy 1:2 put spreads to cap cost) and sell covered calls on ZTS to improve entry. Hedge tail risk with 0.5–1% allocation to 3–6 month VIX call spreads or long TLT if pandemic downside materializes.

Contrarian angles: The market may underweight animal-health winners—Zoetis trades like a mid-single-digit growth name but could see 15–25% upside on government-funded vaccine rollouts; conversely, poultry equities may be oversold if USDA compensation and rebuilding timelines (6–12 months) normalize supply. Historical parallels (2014–2015 avian outbreaks) show sharp price rebounds in large, integrated meat processors once containment and indemnities occur; a pair trade long ZTS/short TSN could capture asymmetric risk. Monitor for mispricings after any major headline spike when volatility transiently overshoots fundamentals.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Zoetis (ZTS) with a 6–12 month horizon; target +20% upside on outsized USDA/industry contracts, set stop-loss at -12% and sell 2–3 month covered calls to improve entry.
• Initiate 1–2% short exposure to poultry/dairy producers: buy 3–6 month put spreads on Tyson Foods (TSN) and Pilgrim’s Pride (PPC) (e.g., buy 25-delta put, sell 10-delta put) sized 0.5–1% each to limit premium spend; exit if herd positives fall <5 herds/month for 2 consecutive months.
• Allocate 1% to commodity exposure via Teucrium Corn Fund (CORN) or nearby corn futures (3–9 month) to capture potential feed-price lift; trim if corn rallies >15% from entry.
• Deploy 0.5–1% as a tail hedge: buy 3–6 month VIX call spreads (e.g., 30/50 strikes) or 3–6 month TLT puts if you prefer interest-rate sensitivity—monitor weekly CDC/USDA human-case bulletins and exit hedge if no human transmission events within 90 days.
• Monitor specific catalysts over the next 30–90 days: (1) any confirmed human-to-human transmission (sell risk assets immediately), (2) USDA vaccine contract awards (add to ZTS/ELAN on announced wins), and (3) monthly USDA herd-positive counts; adjust positions within 7 trading days of each catalyst.